Illumina, Myriad Genetics expand partnership to broaden access to HRD testing in U.S.
Myriad Genetic (NASDAQ:MYGN) and Illumina (NASDAQ:ILMN) announce the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) testing in the U.S.
Under the agreement, Illumina TruSight Oncology 500 HRD (TSO 500 HRD), a research-use-only test, is now available in the U.S.

The expanded partnership also establishes a unique companion diagnostic (CDx) alliance for the pharmaceutical industry, which will enable more clinical research for gene-based, targeted therapies.
Expanding access to HRD research test
The TSO 500 HRD research test aligns Myriadâs gold standard MyChoice CDx HRD technology with Illuminaâs pan-cancer test, TSO 500. The test was codeveloped with Merck and MYGN.
TSO 500 HRD offers a single, comprehensive pan-cancer test to identify key genetic variants and homologous recombination deficiency critical for understanding cancer development and progression. The product is available to order now and ready to ship in the U.S.
New CDx alliance
Under this strategic alliance, Illumina and Myriad will seek joint HRD companion diagnostics partnerships with pharmaceutical companies worldwide (excluding Japan). The joint HRD CDx alliance will aim to pursue HRD regulatory approvals for both the MyChoice HRD Assay companion diagnostic and a future clinical in vitro diagnostic test based off the TSO 500 HRD Assay.